the small-molecule KRAS G12C inhibitor sotorasib combined with the monoclonal antibody panitumumab, had significantly longer progression-free survival compared to those who received standard of care.

Circulating antibodies are highly selective binding reagents directed to a vast repertoire of antigens. Candidate antigens displayed as overlapping peptides on PepStar™ peptide microarrays can ...